货号:GS40287
Galiximab (development code IDEC-114) is an investigational, chimeric (primate/human) monoclonal IgG1 antibody developed for the treatment of B-cell non-Hodgkin lymphoma (NHL). It functions as a targeted immunotherapy against a specific antigen on malignant B cells. Galiximab is designed to bind to its target on the surface of lymphoma cells. Its proposed anti-tumor mechanisms include antibody-dependent cellular cytotoxicity (ADCC) and potentially complement-dependent cytotoxicity (CDC), whereby it recruits and activates immune effector cells (such as natural killer cells and macrophages) to attack and eliminate the bound cancer cells.
科技型中小企业
高新技术企业
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
冉凯凯